Potential significance of high-mobility group protein box 1 in cerebrospinal fluid

• Published in: Heliyon 2023-11, Vol.9 (11), p.e21926-e21926, Article e21926
• Main Authors: Wu, Zhiwu, Liang, Liping, Huang, Qianliang
• Format: Article
• Language: English
• Subjects: Biomarker; biomarkers; brain; Brain function remodeling; Brain-spinal cord connection; cerebrospinal fluid; Cerebrospinal fluid (CSF); cytokines; disease progression; High-mobility group protein box 1 (HMGB1); inflammation; intraventricular injection; nucleoproteins; spinal cord
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2023.e21926

High-mobility group protein box 1 (HMGB1) is a cytokine with multiple functions (according to its subcellular location) that serves a marker of inflammation. CSF HMGB1 could be the part of pathological mechanisms that underlie the complications associated with CNS diseases. HMGB1 actively or passively released into the CSF is detected in the CSF in many diseases of the central nervous system (CNS) and thus may be useful as a biomarker. Pathological alterations in distant areas were observed due to lesions in a specific region, and the level of HMGB1 in the CSF was found to be elevated. Reducing the HMGB1 level via intraventricular injection of anti-HMGB1 neutralizing antibodies can improve the outcomes of CNS diseases. The results indicated that CSF HMGB1 could serve as a biomarker for predicting disease progression and may also act as a pathogenic factor contributing to pathological alterations in distant areas following focal lesions in the CNS. In this mini-review, the characteristics of HMGB1 and progress in research on CSF HMGB1 as a biomarker of CNS diseases were discussed. CSF HMGB1 is useful not only as a biomarker of CNS diseases but may also be involved in interactions between different brain regions and the spinal cord.